Erschienen in:
04.09.2020 | Editorial
Will definitive chemoradiotherapy be a new normal for patients with resectable locally advanced esophageal cancer?
verfasst von:
Hiroya Takeuchi
Erschienen in:
Esophagus
|
Ausgabe 4/2020
Einloggen, um Zugang zu erhalten
Excerpt
Nowadays, neoadjuvant chemotherapy or chemoradiotherapy (CRT) followed by esophagectomy is the standard of care for patients with resectable locally advanced esophageal cancer worldwide [
1‐
3]. On the other hand, for patients unwilling to undergo esophagectomy, definitive CRT has been an alternative treatment for those with advanced esophageal cancer [
4]. However, there are several problems to be resolved for conventional definitive CRT, such as a high incidence of late toxicities and poor survival. …